Valuation: Avacta Group Plc

Market Cap 324M 441M 378M 355M 612M 42.02B 615M 4.2B 1.63B 21.2B 1.65B 1.62B 70.21B P/E 2026 *
-9.9x
P/E 2027 * -10.2x
Enterprise Value 319M 433M 372M 349M 601M 41.29B 604M 4.13B 1.6B 20.83B 1.63B 1.59B 69B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

1 day+0.78%
1 week+3.94%
Current month+3.21%
1 month+3.21%
3 months-6.45%
6 months+7.53%
Current year+20.25%
1 week 0.93
Extreme 0.9283
0.94
1 month 0.9
Extreme 0.9
0.94
Current year 0.74
Extreme 0.7384
1.23
1 year 0.74
Extreme 0.7384
1.23
3 years 0.4
Extreme 0.4011
2.17
5 years 0.4
Extreme 0.4011
2.29
10 years 0
Extreme 0
3.5
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+3.94% - - 441M
+3.31%-3.70%+61.03%+103.64% 70.42B
+2.09%+2.28%+49.95%+91.30% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-1.67%+0.52%+57.12%+10.28% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
-1.68%+0.33%+36.86%-16.09% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+1.15%-1.22%+13.62%+546.01% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average +0.30%+1.16%+59.54%+197.32% 32.03B
Weighted average by Cap. +1.00%+0.72%+56.49%+157.26%

Financials

2026 *2027 *
Net sales - -
Net income -33.4M -45.4M -38.97M -36.57M -63.04M -4.33B -63.35M -433M -168M -2.18B -170M -167M -7.24B -32.74M -44.49M -38.19M -35.84M -61.78M -4.24B -62.08M -424M -164M -2.14B -167M -163M -7.09B
Net Debt -5.58M -7.58M -6.51M -6.11M -10.53M -723M -10.58M -72.27M -28.01M -365M -28.46M -27.84M -1.21B 21.72M 29.52M 25.33M 23.78M 40.99M 2.82B 41.18M 281M 109M 1.42B 111M 108M 4.7B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
25/08/26 $0.9355 +0.78% 5,000
21/08/26 $0.9283 +3.14% 100
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6920GBP
Average target price
0.8167GBP
Spread / Average Target
+18.02%

Annual profits - Rate of surprise